Otcwagon Issues A Follow-up With: Immunoprecise Antibodies Ltd.(ipa)

VICTORIA, British Columbia - March 24, 2020 - PRLog -- ImmunoPrecise Antibodies Ltd. (IPA) is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients.

They recently announced the launch of their PolyTop mAb Therapy to tackle Coronavirus Pandemic.

Current vaccine strategies under development for SARS-CoV-2 are being designed to protect uninfected individuals, however, this does not address the patients with active disease.

Antibody therapies represent a potentially powerful treatment option for COVID-19 patients, however, the current, proposed curative options (including polyclonal, sensitized serum or individual monoclonal antibody therapies) are potentially susceptible to escape by viral mutation and are likely not broadly effective against multiple strains, leaving segments of the population untreatable.

"Given the continuous increase in information on SARS-CoV-2 transmission, and seemingly higher than predicted mutation rates, we believe that traditional treatments and diagnostics targeting limited epitopes may present a significant liability for long-term efficacy of a therapeutic, vaccine or diagnostic", stated ImmunoPrecise CEO and president, Dr. Jennifer Bath.

"Our PolyTope mAb Therapy™ perfectly combines the benefits of using well-defined and fully characterized monoclonal antibodies with the essential need for a multi-targeting strategy to tackle this quickly emerging virus, thereby significantly accelerating effective clinical application".

With the world in crisis, with an uncertain future ahead, ImmunoPrecise Antibodies, Ltd. (IPA) has made it their mission to find a quick, effective solution.

With the undervalued price of $0.63 per share, there has never been a better time to get in… NOW IS THE TIME!